Treating GSM: vaginal estrogen and DHEA
Vaginal dryness, painful intimacy, and recurrent urinary symptoms rarely improve on their own — but they respond well to low-dose local therapy. Here is how vaginal estrogen and DHEA work.
Low-dose vaginal estrogen and vaginal DHEA are the two best-evidenced treatments for GSM, the genitourinary syndrome of menopause. Both act locally on vaginal and urinary tissue — dryness, painful intimacy, and recurrent urinary symptoms — with minimal hormone reaching the bloodstream. Unlike hot flashes, GSM tends to persist or worsen without treatment, per The Menopause Society.
Why is local therapy the right tool for GSM?
GSM is driven by falling estrogen in the vaginal and urinary tissues specifically. That makes it well suited to low-dose local therapy: medication applied where the problem is, with very little hormone reaching the bloodstream. This is a different risk conversation from systemic hormone therapy, and it widens the range of women who are candidates.
Low-dose vaginal estrogen is effective for the genitourinary syndrome of menopause and is associated with minimal systemic absorption.
How does vaginal estradiol work?
Low-dose vaginal estradiol cream — as a cream, insert, or ring — rebuilds the thickness, elasticity, and moisture of tissue that thins as estrogen declines. Because the dose is low and local, only minimal estrogen reaches the bloodstream. Many women begin with a short daily course and then move to a twice-weekly maintenance schedule set by their clinician.
- Relieves dryness, irritation, and painful intimacy at the source.
- Can reduce the frequency of recurrent urinary tract infections.
- Minimal systemic absorption compared with systemic estrogen therapy.
What is vaginal DHEA, and is it a non-estrogen option?
For women who prefer a non-estrogen approach, vaginal DHEA (prasterone) is an alternative. It is converted within the vaginal cells themselves into small amounts of estrogen and androgen that restore the local tissue, while measured systemic hormone levels stay in the postmenopausal range. It is taken as a nightly insert. Womea currently offers vaginal estradiol cream for GSM; we describe DHEA here so you understand the full range of options to discuss with your clinician.
Vaginal DHEA (prasterone) improves moderate to severe dyspareunia due to the genitourinary syndrome of menopause.
| Option | Form | Systemic hormone type |
|---|---|---|
| Vaginal estradiol | Cream, insert, or ring | Estrogen, minimal systemic absorption |
| Vaginal DHEA (prasterone) | Nightly insert | Converted locally to estrogen and androgen |
Is GSM worth treating?
GSM is not a cosmetic concern; it affects comfort, intimacy, sleep, and urinary health, and it tends to compound over time when left alone. Both vaginal estradiol and DHEA are well evidenced. See our full GSM and vaginal health treatment overview for how care is structured. The hardest step is usually raising it with a clinician — which is exactly the conversation this kind of care is built to make easy.
Questions, answered
Often, yes. Low-dose vaginal estrogen acts locally with minimal systemic absorption and is considered appropriate for many women who cannot or prefer not to use systemic hormones. Your clinician reviews your history to confirm.
Explore the related treatments
If this is relevant to you, these are the treatments it most often connects to.
More from the science hub
Transdermal vs oral estrogen: the mechanism and the evidence
Estradiol can be delivered through the skin or swallowed as a pill — and the difference is not cosmetic. Transdermal routes bypass the liver's first pass, which appears to lower clot risk. Here is the mechanism and the evidence behind that difference.
7 min readEstrogen, bone loss, and fracture risk in menopause
Estrogen helps keep bone strong, and its decline drives the fastest bone loss of a woman's life in the years around menopause. Hormone therapy is an established option to prevent that loss — within an individualized, risk-aware decision.
7 min readIs hormone therapy safe? What the evidence says
For most healthy women under 60 or within ten years of menopause, the benefits of hormone therapy outweigh the risks. Here is what the major trials and current guidelines say — and what they do not.
7 min readFeel like yourself again.
Take the 3-minute assessment, then meet your clinician by video or phone. No obligation.